Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case

Mizuki Izawa, Takeo Kosaka, Kohei Nakamura, Junna Oba, Tomoyuki Hishida, Hiroshi Hongo, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Most metastatic prostate cancers acquire the capacity for androgen-independent growth and become resistant to androgen deprivation therapy. A patient-focused treatment strategy is needed for aggressive castration-resistant prostate cancer. Case presentation: We report the case of a 62-year-old man who presented with prostatic adenocarcinoma who was treated by radiation and combined androgen blockade. After completion of first-line therapy, he was diagnosed with multiple metastatic castration-resistant prostate cancer in the lung. Second-line therapy with abiraterone acetate resulted in partial remission of the lung metastases. Thoracic surgery was performed to remove the single lung metastasis remaining. Next-generation sequencing of the specimens demonstrated homozygous loss of BRCA2. We note in this case a heterogeneous response to abiraterone acetate may be related to the somatic BRCA2 deletions. Conclusions: We present the first Japanese case of a metastatic abiraterone acetate-resistant castration-resistant prostate cancer accompanied by BRCA2 mutation.

Original languageEnglish
Pages (from-to)14-17
Number of pages4
JournalIJU Case Reports
Volume4
Issue number1
DOIs
Publication statusPublished - 2021 Jan

Keywords

  • BRCA2
  • DNA damage repair genes
  • abiraterone acetate
  • next-generation sequencing
  • prostate cancer

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case'. Together they form a unique fingerprint.

Cite this